AxoGen, Inc. (NASDAQ:AXGN) Short Interest Update

AxoGen, Inc. (NASDAQ:AXGN) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,010,000 shares, a decrease of 7.3% from the November 30th total of 1,090,000 shares. Based on an average daily trading volume, of 356,700 shares, the short-interest ratio is presently 2.8 days.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

AxoGen Stock Down 0.1 %

AXGN stock traded down $0.01 during trading on Wednesday, hitting $16.48. 589,798 shares of the company’s stock were exchanged, compared to its average volume of 392,300. The business has a 50-day moving average price of $14.32 and a two-hundred day moving average price of $12.23. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $725.25 million, a price-to-earnings ratio of -51.50 and a beta of 1.06. AxoGen has a 52-week low of $5.55 and a 52-week high of $17.23.

Institutional Trading of AxoGen

Several institutional investors have recently modified their holdings of AXGN. Sentry Investment Management LLC grew its stake in AxoGen by 9.3% during the 3rd quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock worth $243,000 after buying an additional 1,483 shares during the last quarter. Quest Partners LLC increased its holdings in shares of AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 2,076 shares during the period. Rhumbline Advisers increased its holdings in shares of AxoGen by 6.2% in the 2nd quarter. Rhumbline Advisers now owns 58,157 shares of the medical equipment provider’s stock valued at $421,000 after acquiring an additional 3,380 shares during the period. nVerses Capital LLC purchased a new stake in AxoGen in the 3rd quarter valued at $56,000. Finally, Franklin Resources Inc. grew its position in AxoGen by 9.8% during the 3rd quarter. Franklin Resources Inc. now owns 76,048 shares of the medical equipment provider’s stock worth $1,084,000 after purchasing an additional 6,767 shares during the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.